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Human skin: a mirror for estrogen action? 
Human skin is a complex organ accounting for 15% of the total body weight of 
an adult. It provides the first line of defence against environmental stress 
including microorganisms, ultraviolet radiation, dehydration or physical 
damage, and regulates body temperature, water balance, excretion and the 
synthesis of vitamin D. Human skin is a heterogeneous tissue composed of 
three main layers, the epidermis, the dermis and the hypodermis. The 
keratinocytes of the epidermis proliferate and differentiate to form a 
waterproof keratinizing squamous epithelium, while the fibroblasts in the 
dermis form the connective tissue, synthesising collagens, reticular and 
elastic fibres and glycoproteins1. Within the dermis are blood and lymphatic 
vessels, and skin appendages e.g. sweat glands, hair follicles and sebaceous 
glands. The hypodermis is a subcutaneous layer composed of insulating fatty 
connective tissue and loose connective tissue; the predominant cell type is 
the adipocyte, although fibroblasts and macrophages may also be found.  
With aging, human skin undergoes profound changes due to atrophy of the 
epidermis, dermis and hypodermis; this results in reduced thickness, an 
increase in number and depth of wrinkles, increased dryness, and decreased 
vascularity, firmness and elasticity2. Skin aging is also associated with 
impaired wound healing which can give rise to non-healing chronic wounds. 
Estrogen modulates all phases of wound healing reducing inflammation, 
accelerating re-epithelialisation, stimulating the formation of granulation tissue 
and regulating proteolysis3. Furthermore, postmenopausal women over the 
age of 65 have been shown to be at a lower risk of developing a venous ulcer 
or a pressure ulcer if they were taking estrogen replacement4. 
While a number of environmental factors including sun exposure and smoking 
can affect the rate at which age-associated skin changes take place, there is 
a plethora of evidence to suggest that onset of the menopause in women 
significantly accelerates it (reviewed5-8). The role of estrogen deficiency in the 
age-associated changes concomitant with the decline in the structural integrity 
and functional capacity of the skin is well recognized. In elderly females the 
decrease in skin thickness and collagen content correlates more closely with 
the period of estrogen deficiency than with chronological age9,10 indeed the 
decrease in skin collagen parallels the reduction in bone mass observed in 
post-menopausal women9.  
 
Many of the reported effects of estrogen on aging human skin have stemmed 
from comparisons of post-menopausal women taking estrogen replacement 
with those who have not. While administration of estrogen clearly has positive 
effects on human skin by delaying or preventing symptoms associated with 
skin aging5,11, understanding these effects is complicated by a number of 
factors. The majority of studies have been observational, and the use of 
different estrogen preparations and doses with, or without, the simultaneous 
use of progesterone or testosterone offers further complications. Thus, 
making true comparisons and conclusions pertaining to the isolated effects of 
estrogen are difficult.  
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The diverse functions of estrogen in a wide range of tissues in both sexes, 
including the bone, brain, skeletal muscle, adipose tissue, colon, vascular 
system and skin is now well recognized, and the loss of estrogen in 
postmenopausal women has a negative impact on many aspects of female 
health, leading to conditions such as osteoporosis and an increased risk of 
cardiovascular disease12. However, menopausal hormone therapy appears to 
offer a complex pattern of risks and benefits. The Women's Health Initiative 
(WHI) trial13 reported an increased breast cancer risk when an estrogenic 
compound was combined with progestin, whereas estrogen alone can have 
protective effects. These studies led to a significant reevaluation of the risks 
and benefits of systemic hormone replacement therapy, with 
recommendations for its use limited to short-term treatment for the relief of 
menopausal symptoms. More than a decade later, while estrogen 
replacement for most newly menopausal women appears to be safe and 
effective14, justifying the use of randomized clinical trials to assess the effects 
of systemic estrogen on skin is still difficult from a risk-benefit point of view. 
 
The study on aging skin reported by Toz et al in this issue is different to 
previous studies, because they have compared a group of women undergoing 
hysterectomy directly with another group undergoing hysterectomy with 
bilateral salpingo-oophorectomy (BSO). Since absence of estrogen clearly 
reduces the possibility of breast and ovarian cancer, hysterectomy with 
bilateral oophorectomy (BSO) is associated with a significant reduction in risk 
for breast and ovarian cancer. Therefore, for women undergoing 
hysterectomy, the opportunity for an elective BSO may appear to be an 
attractive proposition. However, since 65% of hysterectomies are carried out 
on women between the ages of 35-54 years15, if they also elect for a BSO, 
then this will equate to an early menopause and they will be estrogen deficient 
for a significant proportion of their life.  
 
The study considers two groups of pre-menopausal women (41-47years) who 
have been age matched and well-controlled for BMI, smoking status, parity 
and hypertension (Table 1). In order to remove any potential observer bias, 
the skin parameters were scored by the same dermatologist, who was 
unaware of the oophorectomy status of the women. The women were 
evaluated preoperatively and then at 24 and 48 weeks after surgery. Three 
different skin parameters were assessed and using anatomical landmarks, 
ordinal scores of the jowl area, suborbital area and crow’s feet were evaluated 
and given a score for (i) wrinkling, (ii) laxity/sagging, and (iii) texture/dryness. 
 
Intragroup analysis of women who had undergone oophorectomy 
demonstrated a significant deterioration in all three skin parameters at 24 and 
48 weeks (Table 3), although sub-group analysis indicated there was no 
significant deterioration between 24 and 48 weeks. In contrast, intragroup 
analysis of the women who had undergone hysterectomy without 
oophorectomy showed no significant change in any of the parameters. The 
women also completed a Skindex-29 questionnaire16, to particularly assess 
their dermatology-specific quality of life (QOL). Interestingly, scores on 
emotion and symptom subscales that related to their appearance and dry or 
itchy skin were significantly higher in women who had undergone 
oophorectomy. 
 
While these results are not surprising, this study highlights the rapid aging of 
skin in the absence of estrogen, with significant changes observed as early as 
24 weeks of estrogen deprivation. What is not clear is whether this dramatic 
deterioration is an immediate response to estrogen withdrawal. A longer study 
would be useful to determine whether skin aging continues at a similar rate. 
Other useful parameters to evaluate would be changes in the skin 
appendages e.g. the hair follicle and the sebaceous gland. There is limited 
trichogram evidence to suggest that estrogen extends the growing phase of 
the hair cycle to promote hair growth17, while a common treatment-related 
side effect of the use of aromatase inhibitors is scalp hair thinning18. More 
recently a study has described a link between the risk of female pattern hair 
loss and a polymorphism of the gene encoding aromatase19. However, there 
have been no studies of the effect of oophorectomy on the hair cycle of pre-
menopausal women.  
 
The consequence of these changes e.g. dryness, decreased firmness and 
elasticity and appearances of wrinkles is most apparent on the face and other 
sun-exposed areas. In Western societies, women consider the appearance of 
their skin and hair to reflect their general health and well-being, and a 
significant visible acceleration of skin aging may impact on their quality of life. 
While changes to the skin are often overlooked or considered of minor 
importance, in addition to these visual concerns, these marked changes may 
also have more serious implications on skin health such as pressure ulcers 
and venous leg ulcers, and integrity of the genitourinary tract. A recent cross-
sectional study of 460 women aged 25-93 years has reported that a higher 
perceived age (PA) is significantly associated with a lower bone mineral 
density (BMD)/trabecular bone score (TBS) when controlled for chronological 
age20. Therefore, the effects on skin health should also be considered and the 
pre-menopausal patient made fully aware of the detrimental changes that will 
occur to the skin when considering the risk-benefit of an elective 
oophorectomy. 
 
References 
 
 
1. Kanitakis J. Anatomy, histology and immunohistochemistry of normal 
human skin. Eur J Dermatol. 2002;12(4):390-9 
 
2. Montagna W, Carlisle K. Structural changes in ageing skin. Br J 
Dermatol. 1990 Apr;122 Suppl 35:61-70. 
 
3. Emmerson E, Hardman MJ. The role of estrogen deficiency in skin 
ageing and wound healing. Biogerontology. 2012;13:3–20.  
 
4. Margolis DJ, Knauss J, Bilker W. Hormone replacement therapy and 
prevention of pressure ulcers and venous leg ulcers. Lancet. 
2002;359:675–7. 
 
5. Brincat MP. Hormone replacement therapy and the skin. Maturitas. 
2000;35(2):107-17. 
 
6. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin 
Dermatol. 2001;2:143–50. 
 
7. Thornton MJ Estrogens and aging skin. Dermatolendocrinol 2013 5: 
264-70 
 
8. Calleja-Agius J, Brincat M, Borg M. Skin connective tissue and ageing. 
Best Pract Res Clin Obstet Gynaecol. 2013;27(5):727-40 
 
9. Brincat M, Versi E, Moniz CF, Magos A, de Trafford J, Studd JW. Skin 
collagen changes in postmenopausal women receiving different 
regimens of estrogen therapy. Obstet Gynecol. 1987;70:123–7 
 
10. Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, 
Nappi C. Effects of postmenopausal hypoestrogenism on skin collagen. 
Maturitas. 1999;33(3):239-47. 
 
11. Sator PG, Schmidt JB, Rabe T, Zouboulis CC. Skin aging and sex 
hormones in women - clinical perspectives for intervention by hormone 
replacement therapy. Exp Dermatol. 2004;13 Suppl 4:36-40. 
 
12. Wend K, Wend P, Krum SA. Tissue-specifc effects of loss of estrogen 
during menopause and aging. Front Endocrinol (Lausanne) 2012;3:1–
14. 
 
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, 
Stefanick ML, et al. Writing Group for the Women’s Health Initiative 
Investigators. Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results from the Women’s Health 
Initiative randomized controlled trial. JAMA. 2002;288:321–33 
 
14. Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The Women's 
Health Initiative trial and related studies: 10 years later: a clinician's 
view. J Steroid Biochem Mol Biol. 2014;142:4-11. 
 
15. Barber MD: Epidemiology and indications of hysterectomy: changing 
trends. In: Hysterectomy for Benign Disease 2010 chapter 3 pp. 65-76. 
Ed MD Walters, Elsevier Inc. 
 
16. Both H, Essink-Bot ML, Busschbach J, Nijsten T.Critical review of 
generic and dermatology-specific health-related quality of life 
instruments. J Invest Dermatol. 2007;127(12):2726-39.  
 
17. Sinclair R. Hair structure and function In: Handbook of diseases of the 
hair and scalp. 1999 Eds. Sinclair R, Banfiel C, Dawber R New York: 
Blackwell, Oxford Press  
 
16. Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in 
postmenopausal women with breast cancer. Drugs. 2004;64:1213–30
  
19. Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Gene-
wide association study between the aromatase gene (CYP19A1) and 
female pattern hair loss. Br J Dermatol. 2012;161:289–94 
 
20.  Nielsen BR, Linneberg A, Christensen K, Schwarz P. Perceived age is 
associated with bone status in women aged 25-93 years. Age Epub 
2015 Oct 20. 
 
 
 
 
 
